Journal
MOLECULES
Volume 27, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/molecules27072263
Keywords
respiratory syncytial virus; antivirals; viral diseases; respiratory diseases; childhood infections
Funding
- Russian Science Foundation (Moscow, Russia) [21-13-00026]
- Russian Science Foundation [21-13-00026] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
RSVI is a global acute medical and social problem, especially dangerous for infants under one year old and the elderly. Currently, only two drugs are available for clinical use against RSVI and they have limitations. Various research groups are searching for new drugs against RSV, with focus on small molecules, polymeric drugs, and plant extracts.
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI: ribavirin (approved in a limited number of countries due to side effects) and palivizumab (Synagis), which is intended only for the prevention, but not the treatment, of infection. Currently, various research groups are searching for new drugs against RSV, with three main areas of research: small molecules, polymeric drugs (proteins and peptides), and plant extracts. This review is devoted to currently developed protein and peptide anti-RSV drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available